BioCentury | Sep 10, 2018
Distillery Therapeutics

Cancer

...Roche and its Genentech Inc. unit market Tarceva to treat NSCLC, brain and pancreatic cancer. Marina Biotech...
BioCentury | Sep 5, 2018
Company News

Management tracks: Sihuan launches U.S. unit

...and investment at Simcere Pharmaceutical Group (Nanjing, China). French was chairman, president and CEO of Marina Biotech...
BioCentury | May 23, 2018
Distillery Therapeutics

Cancer

...Pfizer Inc. and Astellas Pharma Inc. market Xtandi, an androgen receptor antagonist, for prostate cancer. Marina Biotech...
BioCentury | Oct 19, 2017
Company News

Management tracks: Neurocrine, Cellect, Marina

...who was general manager of Cognate BioServices Inc. (Baltimore, Md.), will succeed Pereg. mRNA company Marina Biotech...
BioCentury | Feb 24, 2017
Company News

Management Tracks

...to serve as the company's CFO. Former CEO Mark Schwartz resigned last month. mRNA company Marina Biotech...
BioCentury | Feb 10, 2017
Company News

Marina Biotech, LipoMedics deal

...milestones. LipoMedics could not be reached, and Marina did not respond in time for publication. Marina Biotech...
...OTCQB:MRNA), City of Industry, Calif. LipoMedics Inc. , City of Industry, Calif. Business: Drug delivery Alicia Parker Marina Biotech...
BioCentury | Sep 26, 2016
Clinical News

MRX34: Phase I discontinued

...using Marina’s SMARTICLES liposomal-based delivery technology (see BioCentury, Jan. 2, 2012 & Jan. 13, 2014). Marina Biotech...
BioCentury | Jun 13, 2016
Clinical News

PNT2258: Interim Phase II data

...Marina’s Smarticles technology to develop and commercialize DNA interference oligonucleotides (see BioCentury, March 19, 2012). Marina Biotech...
...24-base phosphodiester DNA sequence targeting the B cell lymphoma 2 (BCL-2; BCL2) gene formulated with Marina Biotech’s...
BioCentury | May 12, 2016
Distillery Therapeutics

Therapeutics: β-catenin (CTNNB1); ubiquitin specific peptidase 6 (USP6)

...in Phase I/II testing to treat psoriasis and Phase I testing to treat HCV-induced cirrhosis. Marina Biotech...
BioCentury | Apr 11, 2016
Company News

Marina Biotech, Microlin Bio deal

...approval by Marina stockholders and Microlin’s completion of a financing of at least $5 million. Marina Biotech...
Items per page:
1 - 10 of 403
BioCentury | Sep 10, 2018
Distillery Therapeutics

Cancer

...Roche and its Genentech Inc. unit market Tarceva to treat NSCLC, brain and pancreatic cancer. Marina Biotech...
BioCentury | Sep 5, 2018
Company News

Management tracks: Sihuan launches U.S. unit

...and investment at Simcere Pharmaceutical Group (Nanjing, China). French was chairman, president and CEO of Marina Biotech...
BioCentury | May 23, 2018
Distillery Therapeutics

Cancer

...Pfizer Inc. and Astellas Pharma Inc. market Xtandi, an androgen receptor antagonist, for prostate cancer. Marina Biotech...
BioCentury | Oct 19, 2017
Company News

Management tracks: Neurocrine, Cellect, Marina

...who was general manager of Cognate BioServices Inc. (Baltimore, Md.), will succeed Pereg. mRNA company Marina Biotech...
BioCentury | Feb 24, 2017
Company News

Management Tracks

...to serve as the company's CFO. Former CEO Mark Schwartz resigned last month. mRNA company Marina Biotech...
BioCentury | Feb 10, 2017
Company News

Marina Biotech, LipoMedics deal

...milestones. LipoMedics could not be reached, and Marina did not respond in time for publication. Marina Biotech...
...OTCQB:MRNA), City of Industry, Calif. LipoMedics Inc. , City of Industry, Calif. Business: Drug delivery Alicia Parker Marina Biotech...
BioCentury | Sep 26, 2016
Clinical News

MRX34: Phase I discontinued

...using Marina’s SMARTICLES liposomal-based delivery technology (see BioCentury, Jan. 2, 2012 & Jan. 13, 2014). Marina Biotech...
BioCentury | Jun 13, 2016
Clinical News

PNT2258: Interim Phase II data

...Marina’s Smarticles technology to develop and commercialize DNA interference oligonucleotides (see BioCentury, March 19, 2012). Marina Biotech...
...24-base phosphodiester DNA sequence targeting the B cell lymphoma 2 (BCL-2; BCL2) gene formulated with Marina Biotech’s...
BioCentury | May 12, 2016
Distillery Therapeutics

Therapeutics: β-catenin (CTNNB1); ubiquitin specific peptidase 6 (USP6)

...in Phase I/II testing to treat psoriasis and Phase I testing to treat HCV-induced cirrhosis. Marina Biotech...
BioCentury | Apr 11, 2016
Company News

Marina Biotech, Microlin Bio deal

...approval by Marina stockholders and Microlin’s completion of a financing of at least $5 million. Marina Biotech...
Items per page:
1 - 10 of 403